MAZE: HORIZON phase II data shows strong efficacy in AMKD, with pivotal trials and biomarker strategies ahead
Multiple clinical programs are advancing, with key HORIZON phase II data for AMKD expected soon and pivotal trials planned. Early results show strong efficacy and broad patient inclusion, while biomarker strategies and regulatory developments may further shape future studies.Based on Maze Therapeut…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.